Sale to a former director of 6,019 common shares (post-consolidation) together with warrants to purchase up to 6,019 common shares, at a combined purchase price of $332.25 per share and accompanying warrant
| Officer | Age | In this role | Source |
|---|---|---|---|
|
William V. Williams
Also a director
President, Chief Executive Officer and Director
|
71 | Not stated | |
|
Gadi Levin
Chief Financial Officer and Corporate Secretary
|
54 |
Since 2016
10 years
|
|
|
Giuseppe Del Priore
Chief Medical Officer
|
65 |
Since 2022
4 years
|
|
|
Miguel A. Lopez Lago
Chief Scientific Officer
|
56 |
Since 2022
4 years
|
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Sale to a former director of 6,019 common shares (post-consolidation) together with warrants to purchase up to 6,019 common shares, at a combined purchase price of $332.25 per share and accompanying warrant
Grant of 5,833 RSUs to the CEO as compensation for deferred salary, with immediate vesting, offsetting previously accrued compensation owed to the CEO
Loading...